MenACWY vaccine

BIOLOGICAL6 trials

Conditions

ChlamydiaCoronavirusGonorrheaInfections, MeningococcalIron Deficiency AnemiaMeningitis, MeningococcalMeningococcal Vaccines

Phase 1

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

CompletedNCT04886154

GlaxoSmithKlineInfections, Meningococcal

Start: 2021-06-14End: 2024-02-02Updated: 2025-05-31

Phase 2

Investigating a Vaccine Against COVID-19

CompletedNCT04400838

University of OxfordCoronavirus

Start: 2020-05-28End: 2025-02-05Updated: 2025-09-03

Phase 3

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

CompletedNCT04707391

GlaxoSmithKlineMeningitis, Meningococcal

Start: 2021-01-25End: 2023-09-29Updated: 2024-07-03

Unknown Phase

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

CompletedNCT05873751

PfizerChlamydia, Gonorrhea, Meningococcal Vaccines

Start: 2023-04-24End: 2024-03-31Updated: 2025-04-17

Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women

CompletedNCT05919472

Nicole StoffelIron Deficiency Anemia

Start: 2023-07-01End: 2024-07-16Updated: 2025-12-26

Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women

RecruitingNCT06116669

Swiss Federal Institute of TechnologyIron Deficiency Anemia

Start: 2023-11-01End: 2024-12-31Target: 180Updated: 2024-01-24

2025-10-15

A novel approach for estimating vaccine efficacy for infections with multiple outcomes: application to a COVID-19 vaccine trial

AJE Advances Research in Epidemiology2025-10-011 citations

Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults Who Had Previously Received a Meningococcal ACWY Vaccine: A Phase 3, Randomized Controlled Clinical Study

Clinical Infectious Diseases2024-12-263 citations

Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease

Nature Communications2024-04-2223 citations

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.

2022-12-0532 citations

Comparison of blood and lymph node cells after intramuscular injection with HIV envelope immunogens

Frontiers in Immunology2022-10-0515 citations

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

JCI Insight2022-02-2240 citations

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).

2021-09-01208 citations

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial

Nature Communications2021-07-3057 citations

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.

2021-06-18200 citations

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

The Lancet2021-03-30649 citations

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

2021-02-19903 citations

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

2020-12-17477 citations

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

2020-12-083647 citations

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

2020-11-191128 citations